A post hoc analysis of the SUMMIT trial, published in JACC, reveals that baseline body mass index (BMI) and fat distribution ...

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

Hims & Hers delivered strong Q2 growth, driven by compounded GLP-1 offerings, but faces uncertainty as regulatory and supply ...

The updated standard replaces three previous guidelines and reflects the latest thinking on tackling obesity through the ...

Patients ending obesity medication or finishing a weight management programme should be offered support to help keep the ...

People using weight loss medication have been warned it is not a "quick fix" with many at risk of regaining their lost weight ...

Digital health company Noom has started offering lower doses of GLP-1 agonist semaglutide, the active ingredient in Novo Nordisk's weight-loss drug Wegovy, at a knock-down price. The 'microdose' ...

Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...

Doctors at ZAVA warned that these summer staples can cause your blood sugar levels to crash and dehydrate you. This effect ...

Facebook posts reveal more GI side effects from semaglutide drugs like Ozempic than Mounjaro, offering new insights into ...

Dear E.M.: Obstructive sleep apnea is when a person stops breathing during sleep due to obstruction of their airway. Some ...